Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-01
What Is Liraglutide? Benefits, Research & Safety
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Also known as:
Victoza
Saxenda
NN2211
Educational Content Only: This page provides research-based information for educational purposes. Liraglutide is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
GLP-1 Agonists
Half-Life
Approximately 13 hours
UK Status
MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
EU Status
EMA approved for both indications.
Overview
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It was one of the first long-acting GLP-1 analogues, sharing 97% sequence homology with native human GLP-1 but with modifications that extend its duration of action to allow once-daily dosing.
Like native GLP-1, liraglutide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. These effects make it effective for both blood glucose management in type 2 diabetes and weight reduction in obesity.
Liraglutide is marketed under two brand names: Victoza for type 2 diabetes treatment (at doses up to 1.8 mg daily) and Saxenda for chronic weight management (at 3.0 mg daily). Both formulations require once-daily subcutaneous injection.
While semaglutide has since become more prominent due to its greater weight loss efficacy and weekly dosing, liraglutide remains an important option with a longer track record of clinical use and extensive safety data from years of widespread use.
Discovery & History
Liraglutide was developed by Novo Nordisk in the late 1990s and early 2000s as part of the company's GLP-1 research programme. The development was based on understanding that native GLP-1, while therapeutically promising, was rapidly degraded in the body with a half-life of only 1-2 minutes.
The key innovation was the acylation of GLP-1 with a fatty acid chain, enabling the molecule to bind non-covalently to albumin. This dramatically extended its half-life to approximately 13 hours, making once-daily injection practical.
Liraglutide received FDA approval for type 2 diabetes (as Victoza) in 2010 and EMA approval followed. It was one of the most successful diabetes drug launches, demonstrating both glycaemic and cardiovascular benefits.
In 2014, the FDA approved a higher dose of liraglutide (3.0 mg daily) as Saxenda for chronic weight management. This followed the SCALE clinical trial programme demonstrating significant weight loss in people with obesity.
The LEADER cardiovascular outcomes trial, published in 2016, demonstrated that liraglutide reduced the risk of major adverse cardiovascular events in high-risk patients with type 2 diabetes, adding an important benefit to its profile.
Mechanism of Action
Liraglutide activates GLP-1 receptors to produce multiple metabolic effects:
**Glucose-Dependent Insulin Secretion**
Liraglutide stimulates insulin release from pancreatic beta cells only when blood glucose is elevated, reducing hypoglycaemia risk compared to some other diabetes treatments.
**Glucagon Suppression**
The peptide inhibits inappropriate glucagon secretion from pancreatic alpha cells, particularly in the postprandial state, improving glucose control.
**Gastric Emptying Delay**
Liraglutide slows the rate at which food leaves the stomach, contributing to improved post-meal glucose levels and enhanced feelings of fullness.
**Central Appetite Suppression**
GLP-1 receptors in the hypothalamus and brainstem mediate appetite-reducing effects. Liraglutide reduces hunger and promotes satiety, leading to decreased caloric intake.
**Cardiovascular Effects**
Through mechanisms not fully understood but likely involving direct effects on the heart and vasculature as well as improved metabolic parameters, liraglutide provides cardiovascular protection.
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Improved glycaemic control with HbA1c reductions of 1-1.5%
- 2Weight loss averaging 5-8% of body weight (Saxenda dose)
- 3Reduced cardiovascular events in high-risk patients (LEADER trial)
- 4Decreased systolic blood pressure
- 5Improved beta cell function markers
- 6Reduced appetite and food cravings
- 7Improved lipid profiles
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Diabetes: 0.6-1.8 mg daily; Obesity: up to 3.0 mg daily |
| Frequency | Once daily subcutaneous injection |
| Duration | Long-term treatment; gradual dose escalation over several weeks |
| Notes | Liraglutide is a prescription medication requiring medical supervision. Doses are typically escalated gradually to minimise gastrointestinal side effects. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (once daily)
| Half-Life | Stability |
|---|---|
| Approximately 13 hours | Pens should be refrigerated before first use; can be kept at room temperature for up to 30 days after first use |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (especially during initiation)
- Vomiting
- Diarrhoea
- Constipation
- Headache
- Decreased appetite
- Injection site reactions
Rare Risks & Concerns
- Pancreatitis
- Gallbladder disease
- Thyroid tumours (based on rodent studies)
- Hypoglycaemia (especially with concurrent insulin or sulfonylureas)
- Acute kidney injury
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- History of pancreatitis
- Pregnancy and breastfeeding
- Type 1 diabetes
UK & EU Regulatory Context
🇬🇧 United Kingdom
MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
🇪🇺 European Union
EMA approved for both indications.
Liraglutide is a fully approved prescription medication available through legitimate medical channels.
Clinical Studies Summary
LEADER: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Demonstrated 13% reduction in major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
N Engl J Med. 2016;375(4):311-322View on PubMed
SCALE Obesity and Prediabetes: A Randomized, Double-blind, Placebo-controlled Trial
Showed 8% weight loss with liraglutide 3.0 mg vs 2.6% with placebo over 56 weeks.
N Engl J Med. 2015;373(1):11-22View on PubMed
Looking for Liraglutide?
Source research-grade Liraglutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreGLP-1
A natural incretin hormone that regulates blood glucose and appetite, the basis for revolutionary diabetes and obesity medications.
Learn moreSemaglutide
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.
Learn more